About Us

About EpimAb

EpimAb Biotherapeutics is a privately owned biopharmaceutical R&D company based in Shanghai with a proprietary, unique and efficient technology called FIT-IgĀ® (Fabs-In-Tandem Immunoglobulin) that generates bispecific molecules with antibody-like properties. With this innovative platform, EpimAb is creating a potentially game-changing pipeline of its own novel bispecific antibody therapeutics focused around immuno-oncology and other areas of high value to patients.

EpimAb is further committed to diversifying its portfolio of FIT-Igs together with partners in order to further validate the flexibility and robustness of the format and its platform.